Akademik Veri Yönetim Sistemi
Bone Marrow Transplantation, cilt.44, sa.12, ss.779-783, 2009 (SCI-Expanded)
The optimal timing for recombinant human (rh)G-CSF administration after chemotherapy for PBSC mobilization has not yet been determined. In this study, we compared two different time schedules of rhG-CSF; 4th (early) vs 7th day (late), in 48 consecutive patients with multiple myeloma and lymphoma undergoing PBSC mobilization with CE (CY 4gm2 on day 1 and etoposide 200mgm2 on days 1-3). The rhG-CSF dose was 10μgkg/day for all patients. Both groups were comparable in terms of sex, age and number of previously given different chemotherapy regimens. Duration of neutropenia, CD34+ cell count on the first day of apheresis and numbers of aphereses were not statistically different between the two arms. However, the number of doses of rhG-CSF up to the first cycle of apheresis procedures was significantly lower in the late group than in the early group (P=0.005). The median number of total CD34+ cells collected was 10.54 × 106kg (range 0.11-37.27) in the early group and 10.81 × 10 6kg (range 0.17-49.83) in the late group of rhG-CSF (P=0.781). We conclude that PBSC mobilization after late use of rhG-CSF is an effective approach and therefore, in routine clinical practice, late rhG-CSF may be used for PBSC collections after chemotherapy-based mobilization regimens in this cost-conscious era. © 2009 Macmillan Publishers Limited All rights reserved.